Curis raises $47 million in financing:
This article was originally published in Clinica
Executive Summary
Tissue regeneration company Curis has raised nearly $47 million in a private financing. The company is expecting multiple regulatory, clinical and manufacturing milestones early this year and says the fresh funds put it in a strong position to capitalise on these. Nearest to market is OP-1, a product for non-union fractures, which was developed with Stryker and is under regulatory review in the US, Europe and Australia. Curis, based in Cambridge, Massachusetts, is the result of a merger between Creative BioMolecules, Ontogeny and Reprogenesis (see Clinica No 908, p 14).